Adjunctive Antioxidant Therapy in Neurologic Wilson’s Disease Improves the Outcomes

  • Jayantee KalitaEmail author
  • Vijay Kumar
  • Usha K Misra
  • Vasudev Parashar
  • Abhay Ranjan


Oxidative stress has been reported in Wilson’s disease with neurological manifestation (WDNM), but there is a paucity of studies on the role of adjunctive antioxidant therapy. This study aims to evaluate the efficacy of adjunctive vitamin C and E treatment in reducing oxidative stress and improving clinical outcomes. Forty-nine patients with WDNM were included and their clinical details were noted. Glutathione (GSH), total antioxidant capacity (TAC), and malondialdehyde (MDA) were measured using spectrophotometer at baseline and follow-up. All patients received zinc with or without chelating therapy, and 32 of them prescribed vitamin C (500 mg/day) and E (400 mg/day). Clinical outcomes at 6, 12, and 24 months were categorized as improved, static, or worsened based on improvement in Burke-Fahn-Marsden (BFM) score (>10%) and/or severity grade (> 1). Baseline parameters were similar between two groups; except BFM score was higher in the antioxidant group. At follow-up, the antioxidant group had higher GSH, TAC, and lower MDA levels compared with baseline. Patients on antioxidant treatment experienced improvement more frequently at 6 (53.1% vs. 29.4%), 12 (62.5% vs. 29.4%), and 24 months (68.8% vs. 35.3%) compared with those without antioxidant treatment. In WDNM, adjunctive vitamin C and E treatment reduce oxidative stress and improve clinical outcome.


Wilson’s disease  Oxidative stress  Copper  Vitamin C and E 




Compliance with Ethical Standards

Conflict of Interest

On behalf of all the authors, the corresponding author states that there are no conflicts of interest.

Ethics Approval

The research has been approved by the Institutional Ethics Committee, SGPGIMS, Lucknow (Ethic No. A-03: PGI/IMP/IEC/56/19.08.2011).


BFM Burke-Fahn-MarsdenCNS Central nervous systemCu CopperGSH GlutathioneLPO Lipid peroxidation MRI Magnetic resonance imagingMDA MalondialdehydeWD Wilson’s diseaseTAC Total antioxidant capacity


  1. Bernardo-Colon A, Vest V, Clark A, Cooper ML, Calkins DJ, Harrison FE, Rex TS (2018) Antioxidants prevent inflammation and preserve the optic projection and visual function in experimental neurotrauma. Cell Death Dis 9:1097. CrossRefPubMedPubMedCentralGoogle Scholar
  2. Betti M et al (2011) Dietary supplementation with alpha-tocopherol reduces neuroinflammation and neuronal degeneration in the rat brain after kainic acid-induced status epilepticus. Free Radic Res 45:1136–1142. CrossRefPubMedGoogle Scholar
  3. Brewer GJ et al (2009) Treatment of Wilson's disease with tetrathiomolybdate: V. control of free copper by tetrathiomolybdate and a comparison with trientine translational research. J Lab Clin Med 154:70–77. CrossRefGoogle Scholar
  4. Bruha R et al (2012) Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms. J Inherit Metab Dis 35:541–548. CrossRefPubMedGoogle Scholar
  5. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW (1993) The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 5:327–337. CrossRefPubMedGoogle Scholar
  6. Chen DB, Feng L, Lin XP, Zhang W, Li FR, Liang XL, Li XH (2012) Penicillamine increases free copper and enhances oxidative stress in the brain of toxic milk mice. 7:e37709–PloS one. CrossRefGoogle Scholar
  7. Chen H, Pellett LJ, Andersen HJ, Tappel AL (1993) Protection by vitamin E, selenium, and beta-carotene against oxidative damage in rat liver slices and homogenate. Free Radic Biol Med 14:473–482CrossRefGoogle Scholar
  8. Choi BS, Zheng W (2009) Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Res 1248:14–21. CrossRefPubMedGoogle Scholar
  9. Crum RM, Anthony JC, Bassett SS, Folstein MF (1993) Population-based norms for the mini-mental state examination by age and educational level. JAMA 269:2386–2391CrossRefGoogle Scholar
  10. Cummings JL (1997) The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology 48:S10–S16CrossRefGoogle Scholar
  11. Czlonkowska A et al (2018) Wilson disease. Nature reviews Disease primers 4:21. CrossRefPubMedPubMedCentralGoogle Scholar
  12. Dalgic B, Sonmez N, Biberoglu G, Hasanoglu A, Erbas D (2005) Evaluation of oxidant stress in Wsilson's disease and non-Wilsonian chronic liver disease in childhood. Turk J Gastroenterol 16:7–11PubMedGoogle Scholar
  13. European Association for Study of Liver (2012) EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 56:671–685. CrossRefGoogle Scholar
  14. Ferenci P (2017) Diagnosis of Wilson disease. Handbook of clinical neurology 142:171–180. CrossRefGoogle Scholar
  15. Grimm G et al (1991) Comparison of functional and structural brain disturbances in Wilson's disease. Neurology 41:272–276CrossRefGoogle Scholar
  16. Gromadzka G et al (2014) Treatment with D-penicillamine or zinc sulphate affects copper metabolism and improves but not normalizes antioxidant capacity parameters in Wilson disease. Biometals 27:207–215. CrossRefPubMedGoogle Scholar
  17. Guan JZ, Guan WP, Maeda T (2018) Vitamin E administration erases an enhanced oxidation in multiple sclerosis. Can J Physiol Pharmacol 96:1181–1183. CrossRefPubMedGoogle Scholar
  18. Jomova K, Valko M (2011) Advances in metal-induced oxidative stress and human disease. Toxicology 283:65–87. CrossRefPubMedGoogle Scholar
  19. Kalita J, Kumar V, Chandra S, Kumar B, Misra UK (2014a) Worsening of Wilson disease following penicillamine therapy. Eur Neurol 71:126–131. CrossRefPubMedGoogle Scholar
  20. Kalita J, Kumar V, Misra UK (2016) A study on apoptosis and anti-apoptotic status in Wilson disease. Mol Neurobiol 53:6659–6667. CrossRefPubMedGoogle Scholar
  21. Kalita J, Kumar V, Misra UK, Bora HK (2018) Memory and learning dysfunction following copper toxicity: biochemical and immunohistochemical basis. Mol Neurobiol 55:3800–3811. CrossRefPubMedGoogle Scholar
  22. Kalita J, Kumar V, Misra UK, Ranjan A, Khan H, Konwar R (2014b) A study of oxidative stress, cytokines and glutamate in Wilson disease and their asymptomatic siblings. J Neuroimmunol 274:141–148. CrossRefPubMedGoogle Scholar
  23. Kalita J, Kumar V, Ranjan A, Misra UK (2015) Role of oxidative stress in the worsening of neurologic Wilson disease following chelating therapy. NeuroMolecular Med 17:364–372. CrossRefPubMedGoogle Scholar
  24. Kalita J, Misra UK, Kumar V, Parashar V (2019) Predictors of seizure in Wilson disease: a clinico-radiological and biomarkers study. Neurotoxicology 71:87–92. CrossRefPubMedGoogle Scholar
  25. Kalita J, Misra UK, Pradhan PK (2011) Oromandibular dystonia in encephalitis. J Neurol Sci 304:107–110. CrossRefPubMedGoogle Scholar
  26. Kim JJ, Kim YS, Kumar V (2019) Heavy metal toxicity: An update of chelating therapeutic strategies. J Trace Elem Med Biol 54:226–231. CrossRefPubMedGoogle Scholar
  27. Krystkowiak P et al (2007) Reliability of the Burke-Fahn-Marsden scale in a multicenter trial for dystonia. Mov Disord 22:685–689. CrossRefPubMedGoogle Scholar
  28. Kumar V, Kalita J, Bora HK, Misra UK (2016) Relationship of antioxidant and oxidative stress markers in different organs following copper toxicity in a rat model. Toxicol Appl Pharmacol 293:37–43. CrossRefPubMedGoogle Scholar
  29. Litwin T, Dziezyc K, Karlinski M, Chabik G, Czepiel W, Czlonkowska A (2015) Early neurological worsening in patients with Wilson's disease. J Neurol Sci 355:162–167. CrossRefPubMedGoogle Scholar
  30. Mehvari J, Motlagh FG, Najafi M, Ghazvini MR, Naeini AA, Zare M (2016) Effects of vitamin E on seizure frequency, electroencephalogram findings, and oxidative stress status of refractory epileptic patients. Adv Biomed Res 5:36. CrossRefPubMedPubMedCentralGoogle Scholar
  31. Musacco-Sebio R et al (2014) Oxidative damage to rat brain in iron and copper overloads. Metallomics 6:1410–1416. CrossRefPubMedGoogle Scholar
  32. Nagamine T et al (1997) The possible role of zinc and metallothionein in the liver on the therapeutic effect of IFN-alpha to hepatitis C patients. Biol Trace Elem Res 58:65–76CrossRefGoogle Scholar
  33. Nagasaka H, Takayanagi M, Tsukahara H (2009) Children's toxicology from bench to bed--Liver Injury (3): oxidative stress and anti-oxidant systems in liver of patients with Wilson disease. J Toxicol Sci 34(Suppl 2):SP229–SP236PubMedGoogle Scholar
  34. Ogihara H, Ogihara T, Miki M, Yasuda H, Mino M (1995) Plasma copper and antioxidant status in Wilson's disease. Pediatr Res 37:219–226. CrossRefPubMedGoogle Scholar
  35. Pansani AP et al (2018) Long-term monotherapy treatment with vitamin E reduces oxidative stress, but not seizure frequency in rats submitted to the pilocarpine model of epilepsy. Epilepsy Behav 88:301–307. CrossRefPubMedGoogle Scholar
  36. Rana SV, Verma S (1997) Protective effects of GSH, alpha-tocopherol, and selenium on lipid-peroxidation in liver and kidney of copper fed rats. Bull Environ Contam Toxicol 59:152–158. CrossRefPubMedGoogle Scholar
  37. Rey AI, Lopez-Bote CJ (2001) Effect of dietary copper and vitamin E supplementation, and extensive feeding with acorn and grass on longissimus muscle composition and susceptibility to oxidation in Iberian pigs. J Anim Physiol Anim Nutr 85:281–292CrossRefGoogle Scholar
  38. Roberts EA, Schilsky ML, American Association for Study of Liver D (2008) Diagnosis and treatment of Wilson disease: an update. Hepatology 47:2089–2111. CrossRefPubMedGoogle Scholar
  39. Schosinsky KH, Lehmann HP, Beeler MF (1974) Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem 20:1556–1563PubMedGoogle Scholar
  40. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM (2009) Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 1790:1149–1160. CrossRefPubMedPubMedCentralGoogle Scholar
  41. Smirnova J, Kabin E, Järving I, Bragina O, Tõugu V, Plitz T, Palumaa P (2018) Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-Lipoic acid as a potential anti-copper agent. Sci Rep 8:1463–1463. CrossRefPubMedPubMedCentralGoogle Scholar
  42. Sokol RJ, McKim JM Jr, Devereaux MW (1996) alpha-tocopherol ameliorates oxidant injury in isolated copper-overloaded rat hepatocytes. Pediatr Res 39:259–263. CrossRefPubMedGoogle Scholar
  43. Tanzi RE et al (1993) The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 5:344–350. CrossRefPubMedGoogle Scholar
  44. Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW (1995) The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 9:210–217. CrossRefPubMedGoogle Scholar
  45. Tsuchiya H, Bates CJ (1997) Vitamin C and copper interactions in guinea-pigs and a study of collagen cross-links. Br J Nutr 77:315–325CrossRefGoogle Scholar
  46. von Herbay A, de Groot H, Hegi U, Stremmel W, Strohmeyer G, Sies H (1994) Low vitamin E content in plasma of patients with alcoholic liver disease, hemochromatosis and Wilson's disease. J Hepatol 20:41–46CrossRefGoogle Scholar
  47. Wiles C (1990) Quantification of neurologic deficit. Journal of Neurology Neurosurgery & Psychiatry 53:628Google Scholar
  48. Wu P, Dong J, Cheng N, Yang R, Han Y, Han Y (2019) Inflammatory cytokines expression in Wilson's disease. Neurol Sci 40:1059-1066. CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of NeurologySanjay Gandhi Post Graduate Medical SciencesLucknowIndia
  2. 2.Department of BiotechnologyYeungnam UniversityGyeongsanRepublic of Korea

Personalised recommendations